Reply to thread

This will be written off as corporate kool aid but there’s a reason we‘be always outperformed qudexy.  It wasn’t cost or coverage because, despite what we were told, it has always been easier and cheaper to get qudexy or the AG.  It’s because txr actually offers clinical value over IR.  Maybe some of us have said it so many times we take it for granted or don’t believe it anymore but the slower rate of rise actually does lessen SEs.  And the SEs of tpm are not just annoying, they effect daily function.  Less SEs actually does allow patients to get to higher more efficacious doses.  This generic still has to be approved by the FDA and it will do so based on showing bioavailability to qudexy/AG, which has the same if not higher rate of rise as IR.  It might hurt at first if hcps believe it’s a cheaper/easier option of txr but they will see it’s not when patients call back pissed off that their migraines are back or they can’t remember their own name.